Last reviewed · How we verify

Rajesh Pahwa, MD — Portfolio Competitive Intelligence Brief

Rajesh Pahwa, MD pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Mirapex Mirapex marketed Other
Requip PR Requip PR phase 3 Dopamine agonist Dopamine D2 and D3 receptors Neurology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Beijing Bozhiyin T&S Co., Ltd. · 1 shared drug class
  2. Beth Israel Deaconess Medical Center · 1 shared drug class
  3. Britannia Pharmaceuticals Ltd. · 1 shared drug class
  4. Desitin Arzneimittel GmbH · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Intec Pharma Ltd. · 1 shared drug class
  7. Leiden University Medical Center · 1 shared drug class
  8. Axxonis Pharma AG · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Rajesh Pahwa, MD:

Cite this brief

Drug Landscape (2026). Rajesh Pahwa, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/rajesh-pahwa-md. Accessed 2026-05-16.

Related